For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Eisai Sales Up 5.0%, Helped by Growth of New Products
August 5, 2013
- Sales of Eisai’s Obesity Treatment Belviq Exceeds US$10 Million Three Weeks after Launch
August 5, 2013
- Astellas’s First-Quarter Net Profit Down 27% Despite Increases in Sales; 5% Decline in Domestic Sales Due to Impact of Generics
August 5, 2013
- MTPC to Consolidate Domestic Manufacturing Plants, Transferring Ashikaga Plant to CMIC Holdings
August 5, 2013
- Apo Plus to Hire 1,000 Contract MRs by 2013-End
August 2, 2013
- Daiichi Sankyo to Cut 400 to 500 Workers in Europe
August 2, 2013
- Daiichi Sankyo Sales Up 4% in First Quarter, Profits Down due to Ranbaxy Business Slump
August 2, 2013
- Takeda April-June Sales Up 3%, but Operating Profit Logs Double-Digit Fall
August 2, 2013
- Sanofi Files NDA for Prostate Cancer Treatment Cabazitaxel in Japan
August 2, 2013
- Prospects for World’s 1st FD Treatment Remain Unclear; Success Will Depend on Raising Awareness, Role of Endoscopy
August 2, 2013
- Pfizer, Takeda Launch RA Treatment Xeljanz, Prepare for Promoting Proper Use of Drug
August 1, 2013
- Takeda Paid 40 billion Yen to Healthcare Professionals in FY2012
August 1, 2013
- 2 Beijing-Based Wholesalers Could Serve as Point of Contact for Japanese Drug Makers: Mr Yoda of Medipal Holdings
August 1, 2013
- PII Study of Renal Anemia Treatment Codeveloped by FibroGen Starts in Japan: Astellas
August 1, 2013
- Sanofi K.K.’s Payments to Healthcare Professionals Total 9.8 Billion Yen in 2012
July 31, 2013
- Ex-Novartis Employee Had Access to Pre-Locked Data: Third-Party Probe
July 31, 2013
- Novartis Paid 23.6 Billion Yen to Doctors, Medical and Research Institutions in 2012
July 31, 2013
- Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered
July 30, 2013
- Arbekacin Inhalation Solution Enters PI Study in US: Meiji Seika Pharma
July 30, 2013
- Medipal, Mitsubishi Acquire Shares in Chinese Pharma Wholesaler for 8 Billion Yen
July 30, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…